CD19 and Burkitt lymphoma: In addition, direct siRNA silencing of XRCC5 also enhanced low-dose SASP (0.1mM)-induced apoptosis for Burkitt's lymphoma BL-41 cells (Figure S7), while targeting XRCC5 induced no apoptosis for primary human CD19+ B cells isolated from peripheral blood of healthy donor (Figure S5).